Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2013 - 2026)

Amphastar Pharmaceuticals' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $164.5 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 17.37% year-over-year to $164.5 million in Q1 2026; TTM through Mar 2026 was $164.5 million, a 17.37% decrease from a year earlier, with the FY2025 full-year figure at $158.2 million, down 8.98% from the prior year.
• Total Current Liabilities advanced to $164.5 million in Q1 2026 per AMPH's latest filing, from $158.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $258.0 million in Q3 2023 and bottomed at $94.9 million in Q4 2022.
• The 5-year median for Total Current Liabilities is $164.5 million (2026), against an average of $169.6 million.
• Across the five-year window, Total Current Liabilities soared 152.43% in 2023 and plunged 45.49% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $94.9 million in 2022, then surged by 137.62% to $225.4 million in 2023, then slipped by 22.91% to $173.8 million in 2024, then declined by 8.98% to $158.2 million in 2025, then gained by 4.0% to $164.5 million in 2026.
• Per Business Quant, the three latest AMPH Total Current Liabilities figures stand at $164.5 million (Q1 2026), $158.2 million (Q4 2025), and $205.2 million (Q3 2025).